| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature Medicine 25 (9), 1415-1421, 2019 | 431 | 2019 |
| Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition MB Ryan, FF de la Cruz, S Phat, DT Myers, E Wong, HA Shahzade, ... Clinical Cancer Research 26 (7), 1633-1643, 2020 | 345 | 2020 |
| TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma L Goyal, L Shi, LY Liu, FF de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 303 | 2019 |
| A reversible gene trap collection empowers haploid genetics in human cells T Bürckstümmer, C Banning, P Hainzl, R Schobesberger, C Kerzendorfer, ... Nature methods 10 (10), 965-971, 2013 | 116 | 2013 |
| Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer JK Rotow, P Gui, W Wu, VM Raymond, RB Lanman, FJ Kaye, N Peled, ... Clinical Cancer Research 26 (2), 439-449, 2020 | 82 | 2020 |
| Synthetic lethal vulnerabilities of cancer F Fece de la Cruz, BV Gapp, SMB Nijman Annual review of pharmacology and toxicology 55 (1), 513-531, 2015 | 50 | 2015 |
| MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated M Smida, F Fece de La Cruz, C Kerzendorfer, IZ Uras, B Mair, A Mazouzi, ... Nature communications 7 (1), 13701, 2016 | 39 | 2016 |
| Methylation in cell-free DNA for early cancer detection FF de la Cruz, RB Corcoran Annals of Oncology 29 (6), 1351-1353, 2018 | 27 | 2018 |
| Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations A Varkaris, F Fece de la Cruz, EE Martin, BL Norden, N Chevalier, ... Cancer Discovery 14 (2), 227-239, 2024 | 13 | 2024 |
| Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma Q Wu, H Ellis, G Siravegna, AG Michel, BL Norden, F Fece de la Cruz, ... Clinical Cancer Research 30 (1), 198-208, 2024 | 13 | 2024 |
| Epigenetic and transcriptional dysregulation of VWA2 associated with a MYC-driven oncogenic program in colorectal cancer B González, F Fece de la Cruz, JK Samuelsson, A Alibés, S Alonso Scientific Reports 8 (1), 11097, 2018 | 9 | 2018 |
| Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers DA Rubinson, N Tanaka, F Fece de la Cruz, KS Kapner, MH Rosenthal, ... Cancer Discovery 14 (5), 727-736, 2024 | 6 | 2024 |
| Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation JK Rotow, P Gui, W Wu, VM Raymond, RB Lanman, FJ Kaye, N Peled, ... Clin Cancer Res 26, 439-49, 2020 | 4 | 2020 |
| TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019; 9 (8): 1064-1079 … L Goyal, L Shi, LY Liu, FF de la Cruz, JK Lennerz, S Raghavan CD-19-0182.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 4 | |
| Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (12), 1949-1949, 2019 | 3 | 2019 |
| Abstract GS03-10: Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations A Varkaris, FF Cruz, E Martin, B Nordern, N Chevalier, I Leshchiner, ... Cancer Research 84 (9_Supplement), GS03-10-GS03-10, 2024 | | 2024 |
| Abstract LB449: Strategies to overcome resistance to PI3Kalpha-selective inhibitors mediated by acquired alterations in the PI3K/AKT pathway FF Cruz, A Varkaris, EE Martin, BL Norden, N Chevalier, AM Kehlmann, ... Cancer Research 84 (7_Supplement), LB449-LB449, 2024 | | 2024 |
| Abstract LB366: KRASG12C inhibition enhances immunogenicity in KRASG12C-mutant colorectal cancer PS Patel, J Tian, FF Cruz, J Curtis, A Panda, T Oka, S Demehri, ... Cancer Research 84 (7_Supplement), LB366-LB366, 2024 | | 2024 |
| Abstract LB352: KRAS inhibition enhances immunogenicity of KRASG12C colorectal cancer J Tian, FF de la Cruz, K Burke, T Oka, JM Curtis, P Sindurakar, E Wong, ... Cancer Research 83 (8_Supplement), LB352-LB352, 2023 | | 2023 |
| ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer. MB Ryan, FF de la Cruz, LG Ahronian, S Phat, DT Myers, HA Shahzade, ... MOLECULAR CANCER RESEARCH 18 (5), 76-76, 2020 | | 2020 |
Meagan RyanMassachusetts General HospitalVerified email at mgh.harvard.edu
